Skip Navigation or Skip to Content
Blog Author
Cal Loudon

Test Revolutionizing US Transparency Reporting (Clone) (Clone) (Clone)

Featured image: Revolutionizing US Transparency Reporting

With the method of managing the clinical supply chain in clinical trials firmly established through a period of trial and error along with continual adjustment over decades, it is time to take another look at the current paradigm with the new technologies and processes available. Specifically, we will view the growth in understanding for how data integration can bring huge improvements in operational efficiency and lower clinical material waste levels.

Lorem ipsum dolor aliquet non

The Physician Payments Sunshine Act, a United States healthcare law, was passed in 2010 to increase financial transparency between pharmaceutical organizations and healthcare entities, such as Healthcare Organizations (HCO) and Healthcare Professionals (HCP). This requires the disclosure of all Transfer of Value (ToV) between these groups, and the Open Payments System was created by the Centers for Medicare & Medicaid Services (CMS) for pharmaceutical companies to report their transactions.

Open Payments System overview

webpage1

As pharma players rushed towards a quick solution to address the US and global transparency requirements, several segregated systems were created, which worsened existing difficulties with data stewardship.

Challenges Pharma giants are facing with Transparency Reporting

Een huis vol met zekerheden

Een huis vol met zekerheden

  1. 01

    Conduct business & IT stakeholder workshops to learn about:

    • Current and aspirational digital data & analytics capabilities across the focus areas identified earlier
    • Current data platforms and future architecture and technology options
  2. 02

    Conduct business & IT stakeholder workshops to learn about:

    • Current and aspirational digital data & analytics capabilities across the focus areas identified earlier
    • Current data platforms and future architecture and technology options
  3. 03

    Conduct business & IT stakeholder workshops to learn about:

    • Current and aspirational digital data & analytics capabilities across the focus areas identified earlier
    • Current data platforms and future architecture and technology options
  4. 04

    Conduct business & IT stakeholder workshops to learn about:

    • Current and aspirational digital data & analytics capabilities across the focus areas identified earlier
    • Current data platforms and future architecture and technology options
  5. 05

    Conduct business & IT stakeholder workshops to learn about:

    • Current and aspirational digital data & analytics capabilities across the focus areas identified earlier
    • Current data platforms and future architecture and technology options

Share This Blog

We are a globally leading business and technology boutique consultancy for the Life Sciences industry. Our clients are leading companies from pharma, biotech, med tech, healthcare & animal health.

© 2025 Tenthpin AG | Illustrations by: www.till-lauer.ch